new triptans as the "triptans war" [3] . In fact, comparative literature data are often hard to understand because of lack of standardised measures of efficacy and safety for different doses, different ways of administration and different times from the administration [4] . Besides, few comparative studies have been carried out with triptans other than sumatriptan, almost always taken as a reference (Fig. 1) . Indirect comparisons such as meta-analyses only serve as estimates of relative efficacy or safety that cannot substitute the potential usefulness of direct comparative research on a wide population. Moreover, few long-term efficacy and safety studies have been published [5] . Table 2 reports the main pharmacoepidemiological parameters that are needed to evaluate the efficacy and safety of triptans [6, 7] . Compliance may be defined as the extent to which a patient's behaviour conforms to medical advice [8] .
Triptans: the experience of a clinical pharmacologist in clinical practice Abstract Despite the pharmacokinetic differences among triptans and the variety of ways of administration, the clinical differences in every day use of these drugs lack in an accepted decisional tree. In fact, there are a number of comparative trials showing conflicting results with regard to efficacy, onset of action, safety and recurrence incidence. That means that the patient's preference probably is the main criterion for choosing one triptan vs. others. This point of view is probably correct considering also that the main cause of therapy failure is noncompliance. A good migraine care strategy requires a balance in what the patient views as satisfactory, a reasonable compromise between efficacy and tolerability, and a careful follow-up. Improvement in compliance should be the main and more immediate goal for the treatment of migraine attacks.
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factors that alter drug distribution or metabolism, such as renal or hepatic insufficiency, congestive heart failure, anaemia, and alcoholism [11] . It has also been suggested that a patient who is receiving specific drugs or drugs of a certain class may be prone to having an adverse effect; however, few studies on headache patients are available (Table 3). Comparing effective dose sizes, triptans seem to differ in their capacity to cause adverse effects without any relationship between adverse effect frequencies and absolute dose size, logD, or absolute dose-size lipophilicity index (ADLI = absolute dose in mg/LogD). Moreover, because of the triptans' similar high affinity for the 5-HT 1B/1D receptors, adverse effects could be mediated through mechanisms that are unrelated to the intrinsic efficacy at those receptors [12] . In clinical practice, the choice of a triptan depends on a number of factors. First of all, it must be decided to use a triptan instead of another non-specific painkiller medicine.
At the moment a stratified approach for migraine attack therapy is preferred to optimise positive reinforcement due to the efficacy of the therapy; triptans are able to reduce the number of non-responders to usual therapy [13] . In clinical practice, the differences outlined (sometimes with conflicting results) in comparative clinical trials are immediately undetectable, so that the efficacy or safety of different triptans is in many case overlapping for the clinician. In this situation the main point to consider in choosing triptans seems to be the patient's preference. In fact, the difference in direct costs, in Italy, are almost negligible, and the difference in preference by patients can be resumed as the following: 1. Rapidity in onset of action; 2. Consistency in repeated use; 3. Mode of administration; 4. Previous use; 5. Incidence of side effects; 6. Counselling of other patients.
Keeping in mind this point, we can identify the more acceptable drug, optimise the compliance and hope to target the maximum therapeutic effect. A well-informed patient is the first step for a good therapeutic strategy.
In conclusion, the most frequent question is: Which is the best triptan? The best answer to this question is that it is the wrong question! In fact, a patient's expression of treatment reference is a valuable thing to know, not only for the individual's clinical management, but also at the population level for epidemiological and economic reasons. In agreement with Sheftell and Fox [14] , we believe that a good migraine care strategy requires a balance with what the patient views as satisfactory, a reasonable compromise between efficacy and tolerability, and a careful follow-up. 
